e-learning
resources
Breathe
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB
E. Panic
Source:
Breathe 2009; 6: 161
Journal Issue:
December
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Panic. Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB. Breathe 2009; 6: 161
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017
Year: 2017
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Poor treatment outcomes of XDR-TB patients in resource-limited settings
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
MDR/XDR-TB treatment outcome
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Clinical management improves the treatment outcome of MDR-TB patients
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Failure predictors when treating MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
Year: 2021
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Healing predictors when treating MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Impact of social support programme on MDR-TB patients' treatment outcomes
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept